3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Temozolomide
19
Bevacizumab
14
Irinotecan
12
Carboplatin
10
Cyclophosphamide
9
Radiosurgery
8
Lomustine
8
Radiotherapy
7
pembrolizumab
6
Vincristine
6
Topotecan
6
Drug Therapy
6
Surgical Procedures, Operative
5
Etoposide
5
Doxorubicin
5
Cisplatin
5
3-Iodobenzylguanidine
5
trametinib
4
Metformin
4
Gemcitabine
4
Dexamethasone
4
Blood Specimen Collection
4
poly ICLC
3
dabrafenib
3
Vorinostat
3
Trastuzumab
3
Therapeutics
3
Radiation
3
Paclitaxel
3
Observation
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
bempegaldesleukin
×
CNS
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts